<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02483858</url>
  </required_header>
  <id_info>
    <org_study_id>PQR309-003</org_study_id>
    <nct_id>NCT02483858</nct_id>
  </id_info>
  <brief_title>Study of Oral PQR309 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PIQUR Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PIQUR Therapeutics AG</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a nonrandomized, dose escalation Phase I study designed to evaluate the safety and
      tolerability of PQR309 in the treatment of selected patients with advanced solid tumors with
      known activation of AKT/PI3K/mTOR.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>In average 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>All changes from baseline conditions will be reported as adverse events to measure safety and maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicities</measure>
    <time_frame>In average 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Toxicity will be assessed using the NCI Common Toxicity Criteria for Adverse Events (CTCAE). Grade 4 neutropenia; Febrile neutropenia; Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with bleeding; Grade 3 or Grade 4 nausea, vomiting, diarrhea or hyperglycemia despite the use of adequate/maximal medical intervention, ALT/AST (Grade 3 or above) in combination with bilirubin (Grade 2 or above) elevation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics profile of PQR309 Cmax, Tmax, AUC, and T1/2</measure>
    <time_frame>In average 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters, including Cmax, Tmax, AUC, and T1/2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>PQR309</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Different dose evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PQR 309</intervention_name>
    <description>Intervention of this drug may include safety, tolerability, PK and efficacy</description>
    <arm_group_label>PQR309</arm_group_label>
    <other_name>AKT/PI3K/mTOR Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of solid malignancy, for which no
             standard curative or life prolonging therapy is available.

          -  Age ≥ 18

          -  ECOG Performance Status of ≤ 1.

          -  Male and female subjects of child-bearing potential must agree to use double-barrier
             contraceptive measures, oral contraception, or avoidance of intercourse during the
             study and for 90 days after last investigational drug dose received.

          -  Life expectancy of ≥ 12 weeks.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Concomitant anticancer therapy (e.g., chemotherapy, radiotherapy, hormonal,
             immunotherapy).

          -  Major surgery within 14 days prior to starting study drug.

          -  Patients with poorly controlled diabetes mellitus, steroid-induced diabetes mellitus,
             or HbA1c &gt; 7%.

          -  Patient is currently receiving warfarin for treatment, prophylaxis or otherwise.

          -  Patients with symptomatic congestive heart failure, myocardial infarction ≤ 6 months
             prior to enrolment, unstable angina pectoris, serious uncontrolled cardiac
             arrhythmia, symptomatic pericarditis, QTcB &gt; 480 msec on the screening ECG.

          -  Pregnant or nursing (lactating) women.

          -  Patients have any of the following mood disorders (active major depressive episode,
             bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history
             of suicidal attempt or ideation, or homicidal ideation, ≥ CTCAE Grade 3 anxiety).

          -  Patients with a history of interstitial pneumonitis or patients who require chronic
             oxygen.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Adjei, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PIQUR</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Adjei, MD,PhD</last_name>
      <email>Alex.Adjei@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Alex Adjei, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 11, 2016</lastchanged_date>
  <firstreceived_date>May 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oncology, solid tumors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
